| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Net revenues | ||||||
351,318 | 248,069 | 177,026 | 82,888 | 33,087 | 15,490 | 10,359 |
Cost of revenues | ||||||
88,606 | 80,048 | 55,610 | 39,870 | 20,610 | 10,036 | 7,013 |
Impairment of field equipment | ||||||
- | - | - | 6,412 | - | - | - |
Gross profit | ||||||
262,712 | 168,021 | 121,417 | 36,606 | 12,477 | 5,454 | 3,346 |
Operating costs and expenses: | ||||||
Research, development and clinical trials | ||||||
79,003 | 50,574 | 38,103 | 41,467 | 43,748 | 40,381 | 34,797 |
Sales and marketing | ||||||
96,675 | 77,663 | 63,528 | 59,449 | 38,861 | 21,177 | 16,406 |
General and administrative | ||||||
87,948 | 73,456 | 59,114 | 51,007 | 33,864 | 24,052 | 16,602 |
Total operating costs and expenses | ||||||
263,626 | 201,693 | 160,745 | 151,923 | 116,473 | 85,610 | 67,805 |
Operating income (loss) | ||||||
-914 | -33,672 | -39,328 | -115,317 | -103,996 | -80,156 | -64,459 |
Financial expenses (income), net | ||||||
7,910 | 12,270 | 9,169 | 6,147 | 3,151 | 144 | 12,558 |
Income (loss) before income tax | ||||||
-8,824 | -45,942 | -48,497 | -121,464 | -107,147 | -80,300 | -77,017 |
Income tax | ||||||
-1,594 | 17,617 | 13,165 | 10,381 | 4,434 | 382 | 353 |
Net income (loss) | ||||||
-7,230 | -63,559 | -61,662 | -131,845 | -111,581 | -80,682 | -77,370 |
Basic net income (loss) per ordinary share (in usd per share) | ||||||
-0.07 | - | - | - | - | - | - |
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | ||||||
97,237 | - | - | - | - | - | - |
Diluted net income (loss) per ordinary share (in usd per share) | ||||||
-0.07 | - | - | - | - | - | - |
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | ||||||
97,237 | - | - | - | - | - | - |
Basic and diluted net income (loss) per ordinary share (in usd per share) | ||||||
- | -0.69 | -0.70 | -1.54 | -3.67 | -6.46 | -6.73 |
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share (in shares) | ||||||
- | 91,828 | 88,546 | 85,558 | 30,401 | 12,490 | 11,498 |